A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework
Larry D. Lynd, Carlo A. Marra, Mehdi Najafzadeh, Mohsen SadatsafaviVolume:
19
Year:
2010
Language:
english
Pages:
9
DOI:
10.1002/pds.1994
File:
PDF, 643 KB
english, 2010